發(fā)布時(shí)間：2018-04-23 18:34

  本文選題：非酒精性脂肪肝病 + 法尼酯X受體　； 參考：《中國(guó)新藥雜志》2017年14期

【摘要】：非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是21世紀(jì)世界范圍的重要的公共健康問(wèn)題,在中國(guó)也越來(lái)越得到重視。其發(fā)病過(guò)程與胰島素抵抗、肥胖、2型糖尿病及高脂血癥密切相關(guān),由于復(fù)雜的發(fā)病機(jī)制,市場(chǎng)上并沒(méi)有針對(duì)NAFLD的特效藥。目前,一些相應(yīng)的治療藥物包括胰島素增敏劑類、降脂類、抗氧化應(yīng)激類及保肝類藥物等等,也均未能完全逆轉(zhuǎn)NAFLD的發(fā)展。治療NAFLD一線用藥的空缺促使研究者進(jìn)行新穎治療方法的開(kāi)發(fā)。因此,本文將對(duì)各通路的治療靶點(diǎn)及相關(guān)藥物的臨床研究進(jìn)行回顧總結(jié),對(duì)NAFLD的治療進(jìn)行較詳細(xì)的綜述,以期對(duì)研究有效改善NAFLD的藥物提供一些思路。
[Abstract]:Non-alcoholic fatty liver disease (NAFLD) is an important public health problem worldwide in the twenty-first Century. It is also becoming more and more important in China. Its pathogenesis is closely related to insulin resistance, obesity, type 2 diabetes and hyperlipidemia. It is caused by complex pathogenesis and is not targeted at NAFLD in the market. At present, some corresponding therapeutic drugs, including insulin sensitizer, lipid lowering, antioxidant stress and liver preservation drugs, have not completely reversed the development of NAFLD. The treatment of NAFLD front-line medication has prompted the researchers to develop new treatment methods. Therefore, this article will target the treatment of various pathways and the correlation. The clinical research of drugs is reviewed and summarized, and the treatment of NAFLD is reviewed in detail, so as to provide some ideas for studying the drugs that can effectively improve NAFLD.

【作者單位】： 天津大學(xué)藥物科學(xué)與技術(shù)學(xué)院;天士力研究院藥理毒理研究中心;
【分類號(hào)】：R575.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 趙澤華;范建高;;2016年美國(guó)肝病年會(huì)非酒精性脂肪性肝病深度報(bào)道[J];實(shí)用肝臟病雜志;2017年01期

2 耿瑞麗;楊朝菊;馮一民;趙曉云;;非酒精性脂肪肝過(guò)氧化物酶體增殖物激活受體α基因甲基化水平與高脂血癥的相關(guān)性研究[J];營(yíng)養(yǎng)學(xué)報(bào);2016年04期

3 段興平;孟強(qiáng);劉克辛;;非酒精性脂肪性肝炎治療的潛在新靶點(diǎn):核受體FXR[J];世界華人消化雜志;2016年15期

4 徐毓;王來(lái)友;郭姣;;代謝性核受體介導(dǎo)非酒精性脂肪性肝病的研究進(jìn)展[J];廣東藥學(xué)院學(xué)報(bào);2016年03期

5 朱世超;鄭學(xué)敏;張s，

本文編號(hào)：1793122